SELLAS Life Sciences Group ( (SLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Sellas Life Sciences shares are climbing after Alliance Global sharply lifted its price target on the stock, signaling a much more optimistic view of the company’s prospects. The brokerage raised its target to $25 from $10, a move that often draws fresh investor attention and can reset expectations for future gains.
Looking beyond today’s move, Sellas’ strengthened balance sheet and sizable cash reserves give it breathing room to keep funding cancer drug trials without rushing back to the market for cash. However, the company still has no meaningful revenue and continues to burn money, so investors face ongoing risks from potential dilution and the need for more financing if clinical results or market conditions disappoint.
More about SELLAS Life Sciences Group
YTD Price Performance: 211.67%
Average Trading Volume: 9,372,251
Technical Sentiment Signal: Hold
Current Market Cap: $2.38B
For further insights into SLS stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.


